Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.30 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.30 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | GRM8 | O00222 | 1/20 | 0.30 |
| ▸ | GRM6 | O15303 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
| ▸ | MTOR | P42345 | 1/20 | 0.30 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.30 |
| ▸ | PLCB1 | Q9NQ66 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8880684 | 0.83 | RBP4 (0.33) | — | |
| SCHEMBL7972576 | 0.82 | PLG (0.37) | LMNA | |
| Ammonia Solution, Strong SCHEMBL28588874 | 0.81 | RBP4 (0.33) | — | |
| SCHEMBL28722251 | 0.81 | BTK (0.31) | BTKGRM2GRM3GRM4CYP1A2 | |
| SCHEMBL4742520 | 0.80 | CYP4F2 (0.31) | BTK | |
| SCHEMBL4829842 | 0.80 | NPSR1 (0.31) | BTK | |
| SCHEMBL28240411 | 0.79 | CHRM2 (0.32) | CHRM2CHRM1CHRM3 | |
| SCHEMBL2306586 | 0.79 | MAPK1 (0.33) | CHRM2CHRM1CHRM3GRM2GRM3 | |
| SCHEMBL2306584 | 0.79 | MAPK1 (0.33) | CHRM2CHRM1CHRM3GRM2GRM3 | |
| SCHEMBL23293553 | 0.78 | CYP2C19 (0.32) | BTKCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4423075-B1 | CCR6 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2026-03-25 | — | — | EP | disclosed |
| US-20250011313-A1 | CCR6 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-01-09 | — | — | US | disclosed |
| EP-4423075-A1 | CCR6 RECEPTOR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2024-09-04 | — | — | EP | disclosed |
| WO-2023102140-A1 | TMPRSS2 INHIBITORS AND METHODS OF USE | TOPSPIN THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023073082-A1 | CCR6 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-05-04 | — | — | WO | disclosed |
| CN-114213435-B | Preparation and application of bis- (10-deoxydihydroartemisinin) -phloroglucinol derivative | 云白药征武科技(上海)有限公司 | 2023-03-21 | — | — | CN | disclosed |
| CN-114213435-A | Preparation and application of bis- (10-deoxydihydroartemisinin) -phloroglucinol derivative | 云白药征武科技(上海)有限公司 | 2022-03-22 | — | — | CN | disclosed |
| WO-2001054507-A1 | METHODS FOR KILLING NEMATODES AND NEMATODE EGGS USING OXADIAZOLE AND OXAIMIDAZOLE COMPOUNDS | AKKADIX CORPORATION (US) | 2001-08-02 | — | — | WO | disclosed |
| WO-2001054508-A1 | MATERIALS AND METHODS FOR KILLING NEMATODES AND NEMATODE EGGS | AKKADIX CORPORATION (US) | 2001-08-02 | — | — | WO | disclosed |
| WO-2001002375-A1 | PROCESS FOR SYNTHESIZING OXADIAZOLES | CHEMRX ADVANCED TECHNOLOGIES, INC. (US) | 2001-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011313-A1 | CCR6 RECEPTOR MODULATORS | CCR6, CCR1, CCR4 | BTK 1611/4885CHRM2 756/4885CHRM1 1040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.